CY2017005I2 - Μακροκυκλικες ενωσεις κινοξαλινης ως αναστολεις πρωτεασεις ns3 του hcv - Google Patents

Μακροκυκλικες ενωσεις κινοξαλινης ως αναστολεις πρωτεασεις ns3 του hcv

Info

Publication number: CY2017005I2
Authority: CY; Cyprus
Prior art keywords: hcv; quinoxaline; inhibitors; proteins; macrocyclic compounds
Prior art date: 2008-07-22

Application number

CY2017005C

Other languages

English (en)

Other versions

CY2017005I1 (el

Original Assignee

Merck Sharp & Dohme Corp.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-07-22

Filing date

2017-01-20

Publication date

2017-06-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41130248&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2017005(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2017-01-20 Application filed by Merck Sharp & Dohme Corp. filed Critical Merck Sharp & Dohme Corp.

2017-06-28 Publication of CY2017005I2 publication Critical patent/CY2017005I2/el

2017-06-28 Publication of CY2017005I1 publication Critical patent/CY2017005I1/el

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Virology (AREA)
Molecular Biology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Biotechnology (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

CY2017005C 2008-07-22 2017-01-20 Μακροκυκλικες ενωσεις κινοξαλινης ως αναστολεις πρωτεασεις ns3 του hcv CY2017005I1 (el)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US13555908P	2008-07-22	2008-07-22
PCT/US2009/050915 WO2010011566A1 (en)	2008-07-22	2009-07-17	Macrocyclic quinoxaline compounds as hcv ns3 protease inhibitors

Publications (2)

Publication Number	Publication Date
CY2017005I2 true CY2017005I2 (el)	2017-06-28
CY2017005I1 CY2017005I1 (el)	2017-06-28

Family

ID=41130248

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
CY20121101150T CY1113752T1 (el)	2008-07-22	2012-11-28	Μακροκυκλικες ενωσεις κινοξαλινης ως αναστολεις πρωτεασεις ns3 του hcv
CY20141100582T CY1115503T1 (el)	2008-07-22	2014-08-01	Συνδυασμοι μακροκυκλικης ενωσης κινοξαλινης η οποια ειναι αναστολεας ηcv ns3 πρωτεασης με αλλους παραγοντες hcv
CY2017005C CY2017005I1 (el)	2008-07-22	2017-01-20	Μακροκυκλικες ενωσεις κινοξαλινης ως αναστολεις πρωτεασεις ns3 του hcv

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
CY20121101150T CY1113752T1 (el)	2008-07-22	2012-11-28	Μακροκυκλικες ενωσεις κινοξαλινης ως αναστολεις πρωτεασεις ns3 του hcv
CY20141100582T CY1115503T1 (el)	2008-07-22	2014-08-01	Συνδυασμοι μακροκυκλικης ενωσης κινοξαλινης η οποια ειναι αναστολεας ηcv ns3 πρωτεασης με αλλους παραγοντες hcv

Country Status (44)

Country	Link
US (2)	US7973040B2 (el)
EP (3)	EP2540349B1 (el)
JP (1)	JP4920797B2 (el)
KR (1)	KR101313675B1 (el)
CN (1)	CN102159285B (el)
AR (1)	AR072588A1 (el)
AU (1)	AU2009274190B2 (el)
BR (1)	BRPI0916235B8 (el)
CA (1)	CA2731177C (el)
CL (1)	CL2011000145A1 (el)
CO (1)	CO6351757A2 (el)
CR (1)	CR20110089A (el)
CY (3)	CY1113752T1 (el)
DK (2)	DK2540350T3 (el)
DO (1)	DOP2011000023A (el)
EA (1)	EA019327B1 (el)
EC (1)	ECSP11010777A (el)
ES (2)	ES2392611T3 (el)
FR (1)	FR16C1027I2 (el)
HK (2)	HK1173403A1 (el)
HN (1)	HN2011000209A (el)
HR (2)	HRP20120866T1 (el)
HU (1)	HUS1700001I1 (el)
IL (1)	IL210580A (el)
LT (1)	LTC2310095I2 (el)
LU (1)	LUC00002I2 (el)
MA (1)	MA32502B1 (el)
ME (2)	ME02024B (el)
MX (1)	MX2011000826A (el)
MY (1)	MY152070A (el)
NI (1)	NI201100023A (el)
NL (1)	NL300857I2 (el)
NO (1)	NO2017004I1 (el)
NZ (1)	NZ590638A (el)
PE (1)	PE20110212A1 (el)
PL (2)	PL2540350T3 (el)
PT (2)	PT2540350E (el)
RS (2)	RS52534B (el)
SI (2)	SI2540350T1 (el)
SV (1)	SV2011003813A (el)
TN (1)	TN2011000014A1 (el)
TW (1)	TWI441638B (el)
UA (1)	UA100436C2 (el)
WO (1)	WO2010011566A1 (el)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY140680A (en)	2002-05-20	2010-01-15	Bristol Myers Squibb Co	Hepatitis c virus inhibitors
CA2667031C (en) *	2006-10-27	2013-01-22	Merck & Co., Inc.	Hcv ns3 protease inhibitors
US8461107B2 (en) *	2008-04-28	2013-06-11	Merck Sharp & Dohme Corp.	HCV NS3 protease inhibitors
UA100436C2 (en)	2008-07-22	2012-12-25	Mepk Шарп Энд Доме Корп.	Macrocyclic quinoxaline compounds as hcv ns3 protease inhibitors
SI2410844T1 (sl)	2009-03-27	2016-06-30	Merck Sharp & Dohme Corp.	Inhibitorji replikacije virusa hepatitisa C
US20190127365A1 (en)	2017-11-01	2019-05-02	Merck Sharp & Dohme Corp.	Inhibitors of hepatitis c virus replication
CN102458444A (zh) *	2009-05-13	2012-05-16	英安塔制药有限公司	用作丙型肝炎病毒抑制剂的大环化合物
US8937150B2 (en)	2009-06-11	2015-01-20	Abbvie Inc.	Anti-viral compounds
CN102333772B (zh) *	2009-06-11	2013-12-11	雅培制药有限公司	抗病毒化合物
WO2011014487A1 (en)	2009-07-30	2011-02-03	Merck Sharp & Dohme Corp.	Hepatitis c virus ns3 protease inhibitors
NZ605440A (en)	2010-06-10	2014-05-30	Abbvie Bahamas Ltd	Solid compositions comprising an hcv inhibitor
SG188618A1 (en) *	2010-09-21	2013-04-30	Enanta Pharm Inc	Macrocyclic proline derived hcv serine protease inhibitors
EP2621501A4 (en) *	2010-09-29	2014-04-09	Merck Sharp & Dohme	POLYCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS FOR THEIR USE IN THE TREATMENT OF VIRAL DISEASES
US9254292B2 (en)	2010-09-29	2016-02-09	Merck Sharp & Dohme Corp.	Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
WO2012082672A2 (en)	2010-12-14	2012-06-21	Merck Sharp & Dohme Corp.	Process and intermediates for preparing macrolactams
WO2012122716A1 (en)	2011-03-17	2012-09-20	Merck Sharp & Dohme Corp.	Tetracyclic xanthene derivatives and methods of use thereof for treatment of viral diseases
US8957203B2 (en)	2011-05-05	2015-02-17	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US10201584B1 (en)	2011-05-17	2019-02-12	Abbvie Inc.	Compositions and methods for treating HCV
US9249204B2 (en) *	2011-06-01	2016-02-02	Jyant Technologies, Inc.	Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof
WO2013028465A1 (en) *	2011-08-19	2013-02-28	Merck Sharp & Dohme Corp.	Crystal forms of a hcv protease inhibitor
US8492386B2 (en)	2011-10-21	2013-07-23	Abbvie Inc.	Methods for treating HCV
CH707029B1 (de)	2011-10-21	2015-03-13	Abbvie Inc	Verfahren zur Behandlung von HCV, umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin, aber nicht Interferon.
AU2013201532B2 (en)	2011-10-21	2014-10-02	Abbvie Ireland Unlimited Company	Methods for treating HCV
US8466159B2 (en)	2011-10-21	2013-06-18	Abbvie Inc.	Methods for treating HCV
RU2014122154A (ru) *	2011-10-31	2015-12-10	Мерк Шарп И Доум Корп.	Композиции, пригодные для лечения вирусных заболеваний
EP2780026B1 (en) *	2011-11-15	2019-10-23	Merck Sharp & Dohme Corp.	Hcv ns3 protease inhibitors
US9034832B2 (en)	2011-12-29	2015-05-19	Abbvie Inc.	Solid compositions
UA119315C2 (uk) *	2012-07-03	2019-06-10	Гіліад Фармассет Елелсі	Інгібітори вірусу гепатиту с
LT2909205T (lt)	2012-10-19	2016-12-27	Bristol-Myers Squibb Company	9-metilpakeistieji heksadekahidrociklopropa(e)pirolo (1,2-a)(1,4)diazaciklopentadecinilkarbamato dariniai, kaip nestruktūrinės 3 (ns3) proteazės inhibitoriai, skirti hepatito c viruso infekcijų gydymui
WO2014070964A1 (en)	2012-11-02	2014-05-08	Bristol-Myers Squibb Company	Hepatitis c virus inhibitors
US9643999B2 (en)	2012-11-02	2017-05-09	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US9334279B2 (en)	2012-11-02	2016-05-10	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
EP2914614B1 (en)	2012-11-05	2017-08-16	Bristol-Myers Squibb Company	Hepatitis c virus inhibitors
WO2014110687A1 (en)	2013-01-16	2014-07-24	Merck Sharp & Dohme Corp.	Thiazolyl-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases
JP6342922B2 (ja)	2013-03-07	2018-06-13	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	Ｃ型肝炎ウイルス阻害剤
US11484534B2 (en)	2013-03-14	2022-11-01	Abbvie Inc.	Methods for treating HCV
MX2015013224A (es) *	2013-03-15	2015-12-11	Gilead Sciences Inc	Inhibidores macrociclicos y biciclicos del virus de la hepatitis c.
EP3057926A4 (en) *	2013-10-18	2017-07-12	Merck Sharp & Dohme Corp.	Methods and intermediates for preparing macrolactams
WO2015095430A1 (en) *	2013-12-20	2015-06-25	Merck Sharp & Dohme Corp.	Methods and intermediates for the preparation of macrolactams
NZ720887A (en) *	2013-12-23	2018-01-26	Gilead Sciences Inc	Crystalline forms of a macrocyclic hcv ns3 inhibiting tripeptide
WO2015100145A1 (en) *	2013-12-23	2015-07-02	Gilead Sciences, Inc.	Synthesis of a macrocyclic hcv ns3 inhibiting tripeptide
EP3089757A1 (en)	2014-01-03	2016-11-09	AbbVie Inc.	Solid antiviral dosage forms
CN105939715A (zh) *	2014-02-05	2016-09-14	默沙东公司	抗病毒化合物的固定剂量组合
WO2015119919A1 (en) *	2014-02-05	2015-08-13	Merck Sharp & Dohme Corp.	Pharmaceutical composition of selective hcv ns3/4a inhibitors
JP2017518319A (ja) *	2014-06-06	2017-07-06	アッヴィ・インコーポレイテッド	結晶形
WO2017023716A1 (en) *	2015-08-04	2017-02-09	Merck Sharp & Dohme Corp.	Fixed-dose combinations of antiviral compounds
US20180228826A1 (en) *	2015-08-04	2018-08-16	Merck Sharp & Dohme Corp.	Fixed-dose combinations of antiviral compounds
CN105753806B (zh) *	2016-02-02	2018-06-05	厦门市蔚嘉化学科技有限公司	一种利托那韦中间体的非均相合成方法及其应用
US11192914B2 (en)	2016-04-28	2021-12-07	Emory University	Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
EP3454856B1 (en)	2016-05-10	2024-09-11	C4 Therapeutics, Inc.	Heterocyclic degronimers for target protein degradation
WO2017197046A1 (en)	2016-05-10	2017-11-16	C4 Therapeutics, Inc.	C3-carbon linked glutarimide degronimers for target protein degradation
CN109562113A (zh)	2016-05-10	2019-04-02	C4医药公司	用于靶蛋白降解的螺环降解决定子体
CN112661775A (zh) *	2016-05-16	2021-04-16	深圳市塔吉瑞生物医药有限公司	一种取代的大环喹喔啉化合物及其药物组合物及应用
RU2650610C1 (ru)	2017-02-28	2018-04-16	Васильевич Иващенко Александр	Противовирусная композиция и способ ее применения
US20220227806A1 (en) *	2019-06-07	2022-07-21	University Of Massachusetts	Hepatitis c virus ns3/4a protease inhibitors
CN111057045A (zh) *	2019-12-18	2020-04-24	安徽红杉生物医药科技有限公司	Hcv ns3/4a蛋白酶抑制剂中间体及其合成方法、应用
US20230218644A1 (en)	2020-04-16	2023-07-13	Som Innovation Biotech, S.A.	Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
US12083099B2 (en)	2020-10-28	2024-09-10	Accencio LLC	Methods of treating symptoms of coronavirus infection with viral protease inhibitors

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3480613A (en)	1967-07-03	1969-11-25	Merck & Co Inc	2-c or 3-c-alkylribofuranosyl - 1-substituted compounds and the nucleosides thereof
US6128582A (en)	1996-04-30	2000-10-03	Vertex Pharmaceuticals Incorporated	Molecules comprising an IMPDH-like binding pocket and encoded data storage medium capable of graphically displaying them
GB9623908D0 (en)	1996-11-18	1997-01-08	Hoffmann La Roche	Amino acid derivatives
GB9707659D0 (en)	1997-04-16	1997-06-04	Peptide Therapeutics Ltd	Hepatitis C NS3 Protease inhibitors
US6143715A (en)	1997-08-11	2000-11-07	Boehringer Ingelheim (Canada) Ltd.	Hepatitis C inhibitor peptide analogues
DK1003775T3 (da)	1997-08-11	2005-05-30	Boehringer Ingelheim Ca Ltd	Hepatitis C-inhibitorpeptider
IT1299134B1 (it)	1998-02-02	2000-02-29	Angeletti P Ist Richerche Bio	Procedimento per la produzione di peptidi con proprieta' inibitrici della proteasi ns3 del virus hcv, peptidi cosi' ottenibili e peptidi
DK1058686T3 (da)	1998-02-25	2007-03-05	Univ Emory	2'-fluornukleosider
GB9806815D0 (en)	1998-03-30	1998-05-27	Hoffmann La Roche	Amino acid derivatives
ES2281170T3 (es)	1998-03-31	2007-09-16	Vertex Pharmaceuticals Incorporated	Inhibidores de serina proteasas, particularmente proteasa ns3 del virus de la hepatitis c.
GB9812523D0 (en)	1998-06-10	1998-08-05	Angeletti P Ist Richerche Bio	Peptide inhibitors of hepatitis c virus ns3 protease
EP1106626B1 (en)	1998-08-10	2003-05-28	Hokkaido Electric Power Company, Incorporated	Process for the preparation of regular glycopeptides
US6323180B1 (en)	1998-08-10	2001-11-27	Boehringer Ingelheim (Canada) Ltd	Hepatitis C inhibitor tri-peptides
JP2002528499A (ja)	1998-10-29	2002-09-03	ブリストル−マイヤーズスクイブカンパニー	Ｉｍｐｄｈ酵素のインヒビターであるアミノ核誘導化合物
UA74546C2 (en)	1999-04-06	2006-01-16	Boehringer Ingelheim Ca Ltd	Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
US6608027B1 (en)	1999-04-06	2003-08-19	Boehringer Ingelheim (Canada) Ltd	Macrocyclic peptides active against the hepatitis C virus
PT1196414E (pt)	1999-06-25	2003-12-31	Vertex Pharma	Pro-farmacos de inibidores carbamato de impdh
CN1167680C (zh)	1999-12-27	2004-09-22	日本烟草产业株式会社	稠环化合物及其药物用途
US6455508B1 (en)	2000-02-15	2002-09-24	Kanda S. Ramasamy	Methods for treating diseases with tirazole and pyrrolo-pyrimidine ribofuranosyl nucleosides
US6495677B1 (en)	2000-02-15	2002-12-17	Kanda S. Ramasamy	Nucleoside compounds
CN1427722A (zh)	2000-02-18	2003-07-02	希拉生物化学股份有限公司	用核苷类似物治疗或预防黄病毒感染的方法
JP4748911B2 (ja)	2000-04-05	2011-08-17	シェーリングコーポレイション	Ｎ−環状ｐ２部分を含むｃ型肝炎ウイルスの大環状ｎｓ３‐セリンプロテアーゼ阻害剤
AU2001253206A1 (en)	2000-04-05	2001-10-23	Tularik, Inc.	Ns5b hcv polymerase inhibitors
JP2003532643A (ja)	2000-04-13	2003-11-05	フアーマセツト・リミテツド	肝炎ウイルス感染症を治療するための３’−または２’−ヒドロキシメチル置換ヌクレオシド誘導体
MY164523A (en)	2000-05-23	2017-12-29	Univ Degli Studi Cagliari	Methods and compositions for treating hepatitis c virus
AP2006003708A0 (en)	2000-05-26	2006-08-31	Idenix Cayman Ltd	Methods and compositions for treating flavivirusesand pestiviruses
US6448281B1 (en)	2000-07-06	2002-09-10	Boehringer Ingelheim (Canada) Ltd.	Viral polymerase inhibitors
GB0017676D0 (en)	2000-07-19	2000-09-06	Angeletti P Ist Richerche Bio	Inhibitors of viral polymerase
AU8477301A (en)	2000-08-10	2002-02-25	Trustees Boston College	Recyclable metathesis catalysts
US6955174B2 (en)	2000-08-18	2005-10-18	Uryovascular Systems, Inc.	Cryotherapy method for detecting and treating vulnerable plaque
US20030008841A1 (en)	2000-08-30	2003-01-09	Rene Devos	Anti-HCV nucleoside derivatives
AU2001282528A1 (en)	2000-09-01	2002-03-22	Shionogi And Co., Ltd.	Compounds having anti-hepatitis c virus effect
DK2251015T3 (da)	2000-10-18	2013-05-13	Gilead Pharmasset Llc	Modificerede nukleotider til behandling af virusinfektioner og abnorm celleproliferation
US6911428B2 (en)	2000-12-12	2005-06-28	Schering Corporation	Diaryl peptides as NS3-serine protease inhibitors of hepatitis C virus
AU2002230763A1 (en)	2000-12-13	2008-01-03	Bristol-Myers Squibb Pharma Company	Inhibitors of hepatitis c virus ns3 protease
CA2429352A1 (en)	2000-12-15	2002-06-20	Lieven Stuyver	Antiviral agents for treatment of flaviviridae infections
CN1482914A (zh)	2000-12-26	2004-03-17	三菱制药株式会社	丙型肝炎治疗剂
EP1355916B1 (en)	2001-01-22	2007-01-10	Merck & Co., Inc.	Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
GB0114286D0 (en)	2001-06-12	2001-08-01	Hoffmann La Roche	Nucleoside Derivatives
EP1423095B1 (en)	2001-08-14	2016-09-28	Tel Aviv University Future Technology Development L.P.	Lipidated glycosaminoglycan particles and their use in drug and gene delivery for diagnosis and therapy
WO2003026675A1 (en)	2001-09-28	2003-04-03	Idenix (Cayman) Limited	Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside
US7138376B2 (en)	2001-09-28	2006-11-21	Idenix Pharmaceuticals, Inc.	Methods and compositions for treating hepatitis C virus using 4'-modified nucleosides
WO2003062192A1 (en)	2002-01-17	2003-07-31	Smithkline Beecham Corporation	Cycloalkyl ketoamides derivatives useful as cathepsin k inhibitors
GB0201179D0 (en)	2002-01-18	2002-03-06	Angeletti P Ist Richerche Bio	Therapeutic agents
CA2369711A1 (en)	2002-01-30	2003-07-30	Boehringer Ingelheim (Canada) Ltd.	Macrocyclic peptides active against the hepatitis c virus
JP2005527499A (ja)	2002-02-13	2005-09-15	メルク　エンド　カムパニー　インコーポレーテッド	ヌクレオシド化合物を用いてオルトポックスウイルスの複製を阻害する方法
DE60202603T2 (de)	2002-03-28	2005-12-29	Council Of Scientific And Industrial Research	8-(c-beta-d-glucopyranosyl)-7,3',4'-trihydroxyflavone, verfahren zur isolation aus pterocarpus marsupium und pharmazeutische zusammensetzung zur behandlung von diabetes
NZ536123A (en)	2002-05-06	2006-09-29	Genelabs Tech Inc	Nucleoside derivatives for treating hepatitis C virus infection
MY140680A (en)	2002-05-20	2010-01-15	Bristol Myers Squibb Co	Hepatitis c virus inhibitors
JP2005530843A (ja)	2002-06-21	2005-10-13	メルク　エンド　カムパニー　インコーポレーテッド	Ｒｎａ依存性ｒｎａウィルスポリメラーゼ阻害剤としてのヌクレオシド誘導体
JP2006512288A (ja)	2002-06-27	2006-04-13	メルク　エンド　カムパニー　インコーポレーテッド	Ｒｎａ依存性ｒｎａウィルスポリメラーゼ阻害薬としてのヌクレオシド誘導体
EP2799442A1 (en)	2002-06-28	2014-11-05	IDENIX Pharmaceuticals, Inc.	Modified 2' and 3' -nucleoside prodrugs for treating flaviridae infections
KR20050055630A (ko)	2002-06-28	2005-06-13	이데닉스 (케이만) 리미티드	플라비비리다에 감염 치료를 위한 1'-, 2'- 및 3'-변형된뉴클레오시드 유도체
PL374781A1 (en)	2002-06-28	2005-10-31	Idenix (Cayman) Limited	2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
US20060264389A1 (en)	2002-07-16	2006-11-23	Balkrishen Bhat	Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
KR20050037559A (ko)	2002-07-25	2005-04-22	마이크로로직스 바이오테크, 인코포레이티드	항바이러스성 ７-데아자 ｄ-뉴클레오시드 및 그의 용도
CA2494340C (en)	2002-08-01	2012-01-24	Pharmasset Inc.	Compounds with the bicyclo[4.2.1]nonane system for the treatment of flaviviridae infections
CA2499253A1 (en)	2002-09-30	2004-04-08	Genelabs Technologies, Inc.	Nucleoside derivatives for treating hepatitis c virus infection
EP1581207A4 (en)	2002-11-01	2007-07-25	Viropharma Inc	BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING AND PROPHYLAXIS OF VIRAL INFECTIONS WITH HEPATITIS C AND RELATED ILLNESSES
US20040254159A1 (en)	2003-02-27	2004-12-16	Hasvold Lisa A.	Heterocyclic kinase inhibitors
JP4550824B2 (ja)	2003-03-05	2010-09-22	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｃ型肝炎抑制化合物
EP1613353A1 (en)	2003-04-02	2006-01-11	Boehringer Ingelheim International GmbH	Pharmaceutical compositions for hepatitis c viral protease inhibitors
GB0307891D0 (en)	2003-04-04	2003-05-14	Angeletti P Ist Richerche Bio	Chemical compounds,compositions and uses
EP2033654B1 (en)	2003-04-16	2012-05-16	Bristol-Myers Squibb Company	Process for resolving a mixture of alkyl ester enantiomers using an enzyme
US7176208B2 (en)	2003-04-18	2007-02-13	Enanta Pharmaceuticals, Inc.	Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
MY143076A (en)	2003-05-21	2011-02-28	Boehringer Ingelheim Int	Hepatitis c inhibitors compounds
TR201906767T4 (tr)	2003-05-30	2019-05-21	Gilead Pharmasset Llc	Modifiye florlanmış nükleosit analogları.
GB0313250D0 (en)	2003-06-09	2003-07-16	Angeletti P Ist Richerche Bio	Therapeutic agents
ES2276311T3 (es)	2003-06-19	2007-06-16	F. Hoffmann-La Roche Ag	Proceso para praderar derivados de 4' -azidonucleosido.
TW200510425A (en)	2003-08-13	2005-03-16	Japan Tobacco Inc	Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
GB0321003D0 (en)	2003-09-09	2003-10-08	Angeletti P Ist Richerche Bio	Compounds, compositions and uses
GB0323845D0 (en)	2003-10-10	2003-11-12	Angeletti P Ist Richerche Bio	Chemical compounds,compositions and uses
US7132504B2 (en)	2003-11-12	2006-11-07	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
EP1730167B1 (en)	2004-01-21	2011-01-12	Boehringer Ingelheim International GmbH	Macrocyclic peptides active against the hepatitis c virus
PT1719773E (pt)	2004-02-24	2009-06-03	Japan Tobacco Inc	Compostos heterotetracíclicos fundidos e a sua utilização como inibidores da polimerase do hcv
GB0413087D0 (en)	2004-06-11	2004-07-14	Angeletti P Ist Richerche Bio	Therapeutic compounds
GB0416396D0 (en)	2004-07-22	2004-08-25	Angeletti P Ist Richerche Bio	Therapeutic agents
US7153848B2 (en)	2004-08-09	2006-12-26	Bristol-Myers Squibb Company	Inhibitors of HCV replication
DE602005015466D1 (de)	2004-08-23	2009-08-27	Hoffmann La Roche	Antivirale 4'-azidonucleoside
GB0419850D0 (en)	2004-09-07	2004-10-13	Angeletti P Ist Richerche Bio	Therapeutic agents
BRPI0516972A (pt)	2004-10-26	2008-09-30	Angeletti P Ist Ricerche Bio	composto, uso do mesmo, composição farmacêutica, método para inibir a polimerase do vìrus da hepatite c e/ou de tratar ou prevenir uma doença devido ao vìrus da hepatite c, e, processo para preparar um composto
US7834145B2 (en)	2005-03-22	2010-11-16	Merck Sharp & Dohme Corp.	HCV protease substrates
AU2006242475B2 (en) *	2005-05-02	2011-07-07	Merck Sharp & Dohme Corp.	HCV NS3 protease inhibitors
GB0509326D0 (en)	2005-05-09	2005-06-15	Angeletti P Ist Richerche Bio	Therapeutic compounds
US7470664B2 (en)	2005-07-20	2008-12-30	Merck & Co., Inc.	HCV NS3 protease inhibitors
US7462035B2 (en)	2005-07-27	2008-12-09	Physical Optics Corporation	Electrical connector configured as a fastening element
NZ565269A (en)	2005-08-01	2010-03-26	Merck & Co Inc	Macrocyclic peptides as HCV NS3 protease inhibitors
WO2007028789A1 (en)	2005-09-07	2007-03-15	Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa	Quinazoline derivatives as antiviral agents
GB0518390D0 (en)	2005-09-09	2005-10-19	Angeletti P Ist Richerche Bio	Therapeutic compounds
GB0519797D0 (en)	2005-09-29	2005-11-09	Istituto Di Ricerche D Biolog	Therapeutic agents
GB0609492D0 (en)	2006-05-15	2006-06-21	Angeletti P Ist Richerche Bio	Therapeutic agents
US20090203008A1 (en)	2006-06-08	2009-08-13	Ludmerer Steven W	Rapid method to determine inhibitor sensitivity of NS3/4A protease sequences cloned from clinical samples
GB0612423D0 (en)	2006-06-23	2006-08-02	Angeletti P Ist Richerche Bio	Therapeutic agents
PE20080992A1 (es)	2006-06-26	2008-08-06	Enanta Pharm Inc	Quinoxalinil macrociclicos inhibidores de serina proteasa del virus de la hepatitis c
US8138164B2 (en)	2006-10-24	2012-03-20	Merck Sharp & Dohme Corp.	HCV NS3 protease inhibitors
AU2007309488B2 (en) *	2006-10-24	2012-10-11	Merck Sharp & Dohme Corp.	HCV NS3 protease inhibitors
AU2007309546A1 (en)	2006-10-24	2008-05-02	Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A.	HCV NS3 protease inhibitors
CA2667031C (en) *	2006-10-27	2013-01-22	Merck & Co., Inc.	Hcv ns3 protease inhibitors
EP2083844B1 (en)	2006-10-27	2013-11-27	Merck Sharp & Dohme Corp.	Hcv ns3 protease inhibitors
CN101557910B (zh)	2006-11-09	2011-08-17	双刃技术控股瑞典股份公司	毂装置
WO2008112108A1 (en)	2007-03-09	2008-09-18	Merck & Co., Inc.	In vivo hcv resistance to anti-viral inhibitors
EA024359B1 (ru)	2007-06-29	2016-09-30	Джилид Сайэнс, Инк.	Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7
CN101754974B (zh)	2007-07-19	2016-02-03	Msd意大利有限公司	作为抗病毒剂的大环化合物
WO2009064955A1 (en)	2007-11-14	2009-05-22	Enanta Pharmaceuticals, Inc.	Macrocyclic tetrazolyl hepatitis c serine protease inhibitors
CL2008003384A1 (es)	2007-11-14	2009-12-11	Enanta Pharm Inc	Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c.
US8461107B2 (en) *	2008-04-28	2013-06-11	Merck Sharp & Dohme Corp.	HCV NS3 protease inhibitors
UA100436C2 (en)	2008-07-22	2012-12-25	Mepk Шарп Энд Доме Корп.	Macrocyclic quinoxaline compounds as hcv ns3 protease inhibitors

2009
- 2009-07-17 UA UAA201102068A patent/UA100436C2/uk unknown
- 2009-07-17 ES ES09790553T patent/ES2392611T3/es active Active
- 2009-07-17 BR BRPI0916235A patent/BRPI0916235B8/pt active IP Right Grant
- 2009-07-17 ME MEP-2012-463A patent/ME02024B/me unknown
- 2009-07-17 SI SI200930956T patent/SI2540350T1/sl unknown
- 2009-07-17 JP JP2011520110A patent/JP4920797B2/ja active Active
- 2009-07-17 RS RS20120463A patent/RS52534B/en unknown
- 2009-07-17 PT PT121815468T patent/PT2540350E/pt unknown
- 2009-07-17 AU AU2009274190A patent/AU2009274190B2/en active Active
- 2009-07-17 PE PE2011000067A patent/PE20110212A1/es active IP Right Grant
- 2009-07-17 PT PT09790553T patent/PT2310095E/pt unknown
- 2009-07-17 WO PCT/US2009/050915 patent/WO2010011566A1/en active Application Filing
- 2009-07-17 EP EP12181533.6A patent/EP2540349B1/en active Active
- 2009-07-17 RS RS20140375A patent/RS53420B/en unknown
- 2009-07-17 EA EA201170241A patent/EA019327B1/ru active Protection Beyond IP Right Term
- 2009-07-17 PL PL12181546T patent/PL2540350T3/pl unknown
- 2009-07-17 EP EP12181546.8A patent/EP2540350B1/en active Active
- 2009-07-17 CA CA2731177A patent/CA2731177C/en active Active
- 2009-07-17 DK DK12181546.8T patent/DK2540350T3/da active
- 2009-07-17 ME MEP-2014-375A patent/ME02132B/me unknown
- 2009-07-17 US US12/504,955 patent/US7973040B2/en active Active
- 2009-07-17 ES ES12181546.8T patent/ES2491090T3/es active Active
- 2009-07-17 MX MX2011000826A patent/MX2011000826A/es active IP Right Grant
- 2009-07-17 CN CN200980137118.6A patent/CN102159285B/zh active Active
- 2009-07-17 NZ NZ590638A patent/NZ590638A/en unknown
- 2009-07-17 MY MYPI20110310 patent/MY152070A/en unknown
- 2009-07-17 SI SI200930359T patent/SI2310095T1/sl unknown
- 2009-07-17 EP EP09790553A patent/EP2310095B1/en active Active
- 2009-07-17 DK DK09790553.3T patent/DK2310095T3/da active
- 2009-07-17 KR KR1020117003982A patent/KR101313675B1/ko active Protection Beyond IP Right Term
- 2009-07-17 PL PL09790553T patent/PL2310095T3/pl unknown
- 2009-07-21 AR ARP090102779A patent/AR072588A1/es active IP Right Grant
- 2009-07-21 TW TW098124597A patent/TWI441638B/zh active
2011
- 2011-01-11 IL IL210580A patent/IL210580A/en active Protection Beyond IP Right Term
- 2011-01-13 TN TN2011000014A patent/TN2011000014A1/fr unknown
- 2011-01-19 NI NI201100023A patent/NI201100023A/es unknown
- 2011-01-19 CO CO11005448A patent/CO6351757A2/es active IP Right Grant
- 2011-01-20 HN HN2011000209A patent/HN2011000209A/es unknown
- 2011-01-20 DO DO2011000023A patent/DOP2011000023A/es unknown
- 2011-01-20 SV SV2011003813A patent/SV2011003813A/es unknown
- 2011-01-21 EC EC2011010777A patent/ECSP11010777A/es unknown
- 2011-01-21 CL CL2011000145A patent/CL2011000145A1/es unknown
- 2011-01-25 MA MA33556A patent/MA32502B1/fr unknown
- 2011-02-15 CR CR20110089A patent/CR20110089A/es unknown
- 2011-05-20 US US13/112,281 patent/US8080654B2/en active Active
2012
- 2012-10-26 HR HRP20120866AT patent/HRP20120866T1/hr unknown
- 2012-11-28 CY CY20121101150T patent/CY1113752T1/el unknown
2013
- 2013-01-15 HK HK13100581.0A patent/HK1173403A1/xx unknown
- 2013-01-15 HK HK13100580.1A patent/HK1173402A1/xx unknown
2014
- 2014-07-18 HR HRP20140693AT patent/HRP20140693T1/hr unknown
- 2014-08-01 CY CY20141100582T patent/CY1115503T1/el unknown
2016
- 2016-12-26 FR FR16C1027C patent/FR16C1027I2/fr active Active
- 2016-12-29 LT LTPA2016049C patent/LTC2310095I2/lt unknown
- 2016-12-30 NL NL300857C patent/NL300857I2/nl unknown
2017
- 2017-01-03 LU LU00002C patent/LUC00002I2/fr unknown
- 2017-01-10 HU HUS1700001C patent/HUS1700001I1/hu unknown
- 2017-01-20 NO NO2017004C patent/NO2017004I1/no unknown
- 2017-01-20 CY CY2017005C patent/CY2017005I1/el unknown

Also Published As

Publication number	Publication date
CN102159285A (zh)	2011-08-17
AR072588A1 (es)	2010-09-08
FR16C1027I2 (fr)	2017-12-08
HN2011000209A (es)	2013-04-22
EP2540350A1 (en)	2013-01-02
LUC00002I1 (el)	2017-01-19
MX2011000826A (es)	2011-02-23
IL210580A0 (en)	2011-03-31
PL2310095T3 (pl)	2013-03-29
CA2731177C (en)	2013-10-29
CN102159285B (zh)	2014-05-14
DOP2011000023A (es)	2011-03-31
HRP20120866T1 (hr)	2013-01-31
UA100436C2 (en)	2012-12-25
BRPI0916235A8 (pt)	2018-06-12
PL2540350T3 (pl)	2014-10-31
IL210580A (en)	2014-08-31
US20100029666A1 (en)	2010-02-04
HUS1700001I1 (hu)	2017-02-28
EA201170241A1 (ru)	2011-10-31
SI2310095T1 (sl)	2013-01-31
CY1113752T1 (el)	2016-07-27
BRPI0916235B8 (pt)	2021-05-25
NI201100023A (es)	2011-09-20
PE20110212A1 (es)	2011-04-10
RS52534B (en)	2013-04-30
TW201023860A (en)	2010-07-01
SV2011003813A (es)	2011-05-25
ES2392611T3 (es)	2012-12-12
ECSP11010777A (es)	2011-02-28
US8080654B2 (en)	2011-12-20
LUC00002I2 (el)	2017-04-04
MA32502B1 (fr)	2011-07-03
MY152070A (en)	2014-08-15
EP2540350B1 (en)	2014-05-21
JP4920797B2 (ja)	2012-04-18
AU2009274190A1 (en)	2010-01-28
HK1173403A1 (en)	2013-05-16
EP2310095A1 (en)	2011-04-20
ME02132B (me)	2014-08-22
HRP20140693T1 (hr)	2014-11-21
TWI441638B (zh)	2014-06-21
RS53420B (en)	2014-12-31
NL300857I2 (el)	2017-04-25
ME02024B (me)	2015-05-20
TN2011000014A1 (en)	2012-09-05
DK2540350T3 (da)	2014-08-04
PT2310095E (pt)	2012-11-16
BRPI0916235B1 (pt)	2020-09-29
HK1173402A1 (en)	2013-05-16
US7973040B2 (en)	2011-07-05
CO6351757A2 (es)	2011-12-20
CR20110089A (es)	2011-04-27
AU2009274190B2 (en)	2012-07-05
CY1115503T1 (el)	2017-01-04
NO2017004I2 (no)	2017-01-20
KR20110036627A (ko)	2011-04-07
EA019327B1 (ru)	2014-02-28
PT2540350E (pt)	2014-08-27
EP2310095B1 (en)	2012-08-29
SI2540350T1 (sl)	2015-01-30
LTC2310095I2 (lt)	2018-11-12
KR101313675B1 (ko)	2013-10-02
LTPA2016049I1 (lt)	2017-01-25
CY2017005I1 (el)	2017-06-28
BRPI0916235A2 (pt)	2018-03-13
WO2010011566A1 (en)	2010-01-28
CA2731177A1 (en)	2010-01-28
EP2540349A1 (en)	2013-01-02
US20110224134A1 (en)	2011-09-15
ES2491090T3 (es)	2014-09-05
DK2310095T3 (da)	2012-12-10
NO2017004I1 (no)	2017-01-20
CL2011000145A1 (es)	2011-05-06
JP2011528713A (ja)	2011-11-24
EP2540349B1 (en)	2014-02-12
FR16C1027I1 (fr)	2017-02-03
NZ590638A (en)	2012-06-29

Publication	Publication Date	Title
CY2017005I2 (el)	2017-06-28	Μακροκυκλικες ενωσεις κινοξαλινης ως αναστολεις πρωτεασεις ns3 του hcv
LTPA2017034I1 (lt)	2017-11-10	Makrocikliniai iš prolino gauti HCV serino proteazės inhibitoriai
CY2015014I2 (el)	2016-08-31	Μακροκυκλικοι αναστολεις της πρωτεασης σερινης της ηπατιτιδας c
HK1203929A1 (en)	2015-11-06	Inhibitors of hcv ns5a hcv ns5a
ATE501156T1 (de)	2011-03-15	Cyclopropyl-annelierte indolobenzazepine als hcv- ns5b-inhibitoren
ZA201104911B (en)	2012-03-28	Inhibitors of hcv ns5a
EP2125870A4 (en)	2011-04-06	INHIBITORS OF NS3 PROTEASE OF HEPATITIS C
CY2014044I1 (el)	2016-04-13	Μακροκυκλικοι αναστολεις του ιου της ηπατιτιδας c
BRPI0923184A2 (pt)	2019-09-24	inibidores de hcv ns3 protease
ATE524475T1 (de)	2011-09-15	Makrocyclische inhibitoren des hepatitis-c-virus
ATE496908T1 (de)	2011-02-15	Makrocyclische inhibitoren des hepatitis-c-virus
ATE455775T1 (de)	2010-02-15	Makrocyclische inhibitoren des hepatitis-c-virus
ATE517902T1 (de)	2011-08-15	Makrocyclische inhibitoren des hepatitis-c-virus
ATE496042T1 (de)	2011-02-15	Makrocyclische inhibitoren des hepatitis-c-virus
ATE496934T1 (de)	2011-02-15	Makrocyclische inhibitoren des hepatitis-c-virus
BRPI0807887A2 (pt)	2014-06-17	Compostos macrocíclicos como inibidores de hcv ns3 protease.
ATE543816T1 (de)	2012-02-15	Azacycloalkanderivate als inhibitoren von stearoyl-coenzym-a-delta-9-desaturase
DE602008003777D1 (de)	2011-01-13	Schwefelverbindungen als hemmer der ns3-serin-protease des hepatitis-c-virus
BR112013010836A2 (pt)	2019-09-24	inibidores específicos de ns3 protease de hcv
TH0901005440A (th)	2016-12-02	ตัวยับยั้งของ hcv ns5a